The present disclosure discloses recombinant Escherichia coli and application thereof in screening erythritol-producing strains, and belongs to the technical field of microorganisms. The recombinant Escherichia coli used in a method for screening an erythritol-producing strain disclosed by the present disclosure can well perform positive correlation induction on erythritol with different concentrations, so that the method for screening the erythritol-producing strain has the advantage of high sensitivity. High-concentration glucose is usually adopted as a fermentation substrate when erythritol is produced in a fermentation mode in the industry, but the method for screening the erythritol-producing strain disclosed by the present disclosure can overcome the interference of the high-concentration glucose, and under the interference of the high-concentration glucose, the recombinant Escherichia coli used in the method for screening the erythritol-producing strain can still well perform positive correlation induction on erythritol with different concentrations, and the correlation is higher than that without the interference of the glucose. Therefore, the method for screening the erythritol-producing strain has the advantage of strong anti-interference capability.

The present disclosure relates to a fusion protein comprising BP26 and an antigenic polypeptide, and to a nanoarchitecture comprising same. A vaccine composition comprising the fusion protein, nanoarchitecture, or combination thereof of the present disclosure can be used to effectively prevent or treat pathogens or cancer, and thus can be used as a multi-purpose vaccine platform.

The present disclosure relates to a fusion protein comprising BP26 and an antigenic polypeptide, and to a nanoarchitecture comprising same. A vaccine composition comprising the fusion protein, nanoarchitecture, or combination thereof of the present disclosure can be used to effectively prevent or treat pathogens or cancer, and thus can be used as a multi-purpose vaccine platform.

The present disclosure discloses recombinant Escherichia coli and application thereof in screening erythritol-producing strains, and belongs to the technical field of microorganisms. The recombinant Escherichia coli used in a method for screening an erythritol-producing strain disclosed by the present disclosure can well perform positive correlation induction on erythritol with different concentrations, so that the method for screening the erythritol-producing strain has the advantage of high sensitivity. High-concentration glucose is usually adopted as a fermentation substrate when erythritol is produced in a fermentation mode in the industry, but the method for screening the erythritol-producing strain disclosed by the present disclosure can overcome the interference of the high-concentration glucose, and under the interference of the high-concentration glucose, the recombinant Escherichia coli used in the method for screening the erythritol-producing strain can still well perform positive correlation induction on erythritol with different concentrations, and the correlation is higher than that without the interference of the glucose. Therefore, the method for screening the erythritol-producing strain has the advantage of strong anti-interference capability.

The present invention provides a Brucellosis cell immune protein and use thereof. In the present invention, firstly, a Brucellosis cell immune protein with relatively high immunogenicity is screened by means of antibody spectrum technology; then, the protein gene sequence of Brucella are subjected to fusion expression by using molecular biology technology, so as to improve the ability for producing an immune response which is induced by an antigen; next, the antigen is expressed in vitro and then subjected to multi-stage purification, and the obtained purified protein is used as a stimulant; and finally, anti-coagulated blood from an immunized animal is collected, the stimulant is added thereto, the mixture is incubated for 24 hours at 37 C., the resulting product is centrifuged to collect a supernatant, and the level of IL-17 in the supernatant is detected by an ELISA method.

The present invention provides a Brucellosis cell immune protein and use thereof. In the present invention, firstly, a Brucellosis cell immune protein with relatively high immunogenicity is screened by means of antibody spectrum technology; then, the protein gene sequence of Brucella are subjected to fusion expression by using molecular biology technology, so as to improve the ability for producing an immune response which is induced by an antigen; next, the antigen is expressed in vitro and then subjected to multi-stage purification, and the obtained purified protein is used as a stimulant; and finally, anti-coagulated blood from an immunized animal is collected, the stimulant is added thereto, the mixture is incubated for 24 hours at 37 C., the resulting product is centrifuged to collect a supernatant, and the level of IL-17 in the supernatant is detected by an ELISA method.